Labyrinthitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LBY004 MIFTS: 40	Labyrinthitis Categories: Ear diseases, Infectious diseases, Neuronal diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Labyrinthitis

MalaCards integrated aliases for Labyrinthitis:

Name: Labyrinthitis ¹² ⁷⁷ ⁴⁵ ¹⁵ ¹⁷ ⁷⁴

Labyrinthine Disorder ⁷⁴

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Ear diseases Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Diseases of the ear and mastoid process

Diseases of inner ear

Other diseases of inner ear

Labyrinthitis

External Ids:

Disease Ontology ¹² DOID:1468

ICD9CM ³⁶ 386.3 386.30

MeSH ⁴⁵ D007762

SNOMED-CT ⁶⁹ 23919004

ICD10 ³⁴ H83.0 H83.09

EFO ¹⁷ EFO_0009604

UMLS ⁷⁴ C0022890 C0022893

Sources

Summaries for Labyrinthitis

Disease Ontology : ¹² An otitis interna which involves inflammation of the labyrinths.

MalaCards based summary : Labyrinthitis, also known as labyrinthine disorder, is related to purulent labyrinthitis and focal labyrinthitis, and has symptoms including vertigo and earache. An important gene associated with Labyrinthitis is CRLF1 (Cytokine Receptor Like Factor 1). The drugs Histamine and Dimenhydrinate have been mentioned in the context of this disorder. Affiliated tissues include testes, eye and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : ⁷⁷ Labyrinthitis, also known as vestibular neuritis, is the inflammation of the inner ear. It results in a... more...

Sources

Related Diseases for Labyrinthitis

Diseases in the Labyrinthitis family:

Viral Labyrinthitis

Diseases related to Labyrinthitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)

#	Related Disease	Score
1	purulent labyrinthitis	12.5
2	focal labyrinthitis	12.5
3	viral labyrinthitis	12.4
4	toxic labyrinthitis	12.4
5	serous labyrinthitis	12.3
6	bilateral hyperactive labyrinth	12.1
7	unilateral hyperactive labyrinth	12.1
8	bilateral hypoactive labyrinth	12.1
9	unilateral hypoactive labyrinth	12.0
10	inner ear disease	11.8
11	meniere disease	11.5
12	otosclerosis	11.4
13	vestibular neuronitis	11.1
14	cochlear disease	11.1
15	otitis media	10.5
16	meningitis	10.5
17	ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus	10.4
18	sensorineural hearing loss	10.2
19	suppurative otitis media	10.2
20	vertigo, benign recurrent	10.1
21	mastoiditis	10.1
22	benign paroxysmal positional nystagmus	10.1
23	otosclerosis 1	10.1
24	mumps	10.1
25	facial paralysis	10.1
26	sudden sensorineural hearing loss	10.1
27	cholesteatoma of middle ear	10.0
28	neurilemmoma	10.0
29	pneumococcal meningitis	10.0
30	thrombosis	9.9
31	acoustic neuroma	9.9
32	dementia	9.9
33	chronic purulent otitis media	9.9
34	neuritis	9.9
35	herpes simplex	9.9
36	pathologic nystagmus	9.9
37	autoimmune inner ear disease	9.9
38	congenital cytomegalovirus	9.9
39	spondyloenchondrodysplasia	9.9
40	headache	9.9
41	autoimmune disease	9.8
42	popliteal pterygium syndrome	9.8
43	diabetes mellitus, noninsulin-dependent	9.8
44	lipomatosis, multiple	9.8
45	motion sickness	9.8
46	osteoporosis	9.8
47	raynaud disease	9.8
48	torticollis	9.8
49	osteoid osteoma	9.8
50	retinitis pigmentosa-deafness syndrome	9.8

Comorbidity relations with Labyrinthitis via Phenotypic Disease Network (PDN): (show all 22)

Anxiety	Basilar Artery Insufficiency
Benign Essential Hypertension	Bronchitis
Cerebrovascular Disease	Chronic Myocardial Ischemia
Esophagitis	Generalized Atherosclerosis
Hypertension, Essential	Hypothyroidism
Inner Ear Disease	Intermediate Coronary Syndrome
Ischemic Heart Disease	Meniere Disease
Otitis Media	Pathologic Nystagmus
Peripheral Vertigo	Transient Cerebral Ischemia
Vertebral Artery Insufficiency	Vertigo, Benign Recurrent
Vestibular Nystagmus	Viral Labyrinthitis

Graphical network of the top 20 diseases related to Labyrinthitis:

Sources

Symptoms & Phenotypes for Labyrinthitis

UMLS symptoms related to Labyrinthitis:

vertigo, earache

GenomeRNAi Phenotypes related to Labyrinthitis according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-143	9.17	IGBP1
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-208	9.17	IGBP1 NCS1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-30	9.17	NCS1
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	9.17	IGBP1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	9.17	IGBP1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-83	9.17	NCS1

Sources

Drugs & Therapeutics for Labyrinthitis

Drugs for Labyrinthitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Histamine

Approved, Investigational

Phase 4,Phase 3,Not Applicable

51-45-6

774

Dimenhydrinate

Approved

Phase 4,Phase 3

523-87-5

441281

Betahistine

Approved, Investigational

Phase 4,Not Applicable

5638-76-6

2366

Sodium Citrate

Approved, Investigational

Phase 4

68-04-2

Caffeine

Approved

Phase 4

58-08-2

2519

Metoclopramide

Approved, Investigational

Phase 4

364-62-5

4168

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Calcium Carbonate

Approved, Investigational

Phase 4

471-34-1

Tocopherol

Approved, Investigational

Phase 4

1406-66-2

14986

Nicotinamide

Approved, Investigational

Phase 4

98-92-0

936

Thymol

Approved

Phase 4

89-83-8

6989

Ethanol

Approved

Phase 4

64-17-5

702

Glycerol

Approved, Investigational

Phase 4

56-81-5

753

Phenol

Approved, Experimental

Phase 4,Not Applicable

108-95-2

996

Methylprednisolone hemisuccinate

Approved

Phase 4,Phase 2,Phase 3

2921-57-5

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3

83-43-2

6741

Prednisolone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3

50-24-8

5755

Prednisolone phosphate

Approved, Vet_approved

Phase 4,Phase 2,Phase 3

302-25-0

Betamethasone

Approved, Vet_approved

Phase 4

378-44-9

9782

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Ergocalciferol

Approved, Nutraceutical

Phase 4

50-14-6

5280793

Calcium

Approved, Nutraceutical

Phase 4,Phase 3,Phase 1

7440-70-2

271

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4

1406-16-2

Vitamin D3

Approved, Nutraceutical

Phase 4

67-97-0

5280795 6221

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 3

59-30-3

6037

Vitamin E

Approved, Nutraceutical, Vet_approved

Phase 4

59-02-9

14985

Niacin

Approved, Investigational, Nutraceutical

Phase 4

59-67-6

938

Tocotrienol

Investigational

Phase 4

6829-55-6

Prednisolone hemisuccinate

Experimental

Phase 4,Phase 2,Phase 3

2920-86-7

Histamine Phosphate

Phase 4,Phase 3,Not Applicable

51-74-1

65513

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Histamine H1 Antagonists

Phase 4,Phase 3,Not Applicable

Autonomic Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Gastrointestinal Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Histamine Antagonists

Phase 4,Phase 3,Not Applicable

Antiemetics

Phase 4,Phase 3,Phase 2,Not Applicable

Pharmaceutical Solutions

Phase 4,Phase 2

Vasodilator Agents

Phase 4,Phase 1,Not Applicable

Sildenafil Citrate

Phase 4

171599-83-0

Phosphodiesterase Inhibitors

Phase 4,Not Applicable

Citrate

Phase 4

Phosphodiesterase 5 Inhibitors

Phase 4

Central Nervous System Stimulants

Phase 4

Purinergic P1 Receptor Antagonists

Phase 4

Dopamine Antagonists

Phase 4

Dopamine Agents

Phase 4

Dopamine D2 Receptor Antagonists

Phase 4

Trace Elements

Phase 4

Vitamins

Phase 4

Interventional clinical trials:

(show top 50) (show all 204)

#	Name	Status	NCT ID	Phase	Drugs
1	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients	Unknown status	NCT00132223	Phase 4	Contrast agent
2	Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets	Completed	NCT02718846	Phase 4	Meniace;Isobide
3	Efficacy of Local Overpressure Treatment for Meniere's Disease	Completed	NCT00831688	Phase 4
4	Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy	Completed	NCT00160238	Phase 4	Betahistine 24 mg bid (Betaserc)
5	Sildenafil For Meniere's Disease	Completed	NCT00145483	Phase 4	Sildenafil
6	Effect of Caffeine Intake in Vestibular Function	Completed	NCT02825199	Phase 4
7	Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo	Completed	NCT01890538	Phase 4	Administration of 100 mg dimenhydrinate intravenous;2 g piracetam intravenous
8	Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo	Completed	NCT02253524	Phase 4	Dimenhydrinate;Metoclopramide
9	Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV	Completed	NCT02031692	Phase 4	400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
10	Effect of Stellate Ganglion Block on Meniere's Disease	Completed	NCT01574313	Phase 4	0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
11	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal	Completed	NCT00765635	Phase 4	drops intilation (Taponoto ® );drops intilation (Otocerum®);drops intilation (Placebo)
12	Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease	Recruiting	NCT02530931	Phase 4	Gadolinium
13	Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)	Recruiting	NCT02529475	Phase 4	Gadoteric acid
14	Acute Unilateral Vestibulopathy and Corticosteroid Treatment	Recruiting	NCT02912182	Phase 4	Betamethasone;Placebo;Prednisolone
15	A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation	Withdrawn	NCT00474409	Phase 4	Merislon
16	Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin	Unknown status	NCT02112578	Phase 3	Meclizine;Dimenhydrinate
17	Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease	Unknown status	NCT01729767	Phase 2, Phase 3	Acyclovir;Placebo
18	Conventional Versus Virtual Reality Based Vestibular Rehabilitation	Completed	NCT01442623	Phase 2, Phase 3
19	Study of OTO-104 in Subjects With Unilateral Meniere's Disease	Completed	NCT02612337	Phase 3	OTO-104;Placebo
20	Clinical Trial of Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease	Completed	NCT01454726	Phase 3
21	Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease	Completed	NCT00802529	Phase 2, Phase 3	Methylprednisolone;Gentamicin
22	Study of Lamotrigine to Treat Ménière's Disease	Completed	NCT02158585	Phase 3	Lamotrigine;Placebo
23	The Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo	Completed	NCT02029508	Phase 3
24	Promethazine vs. Lorazepam for Treatment of Vertigo	Completed	NCT01827293	Phase 3	Promethazine;Lorazepam
25	Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo	Completed	NCT01366430	Phase 3
26	Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo	Completed	NCT00810641	Phase 3
27	Canalith Repositioning Procedure for BPPV in Primary Care	Completed	NCT00182273	Phase 3
28	Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria	Completed	NCT00785135	Phase 3
29	Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease	Recruiting	NCT03664674	Phase 3	OTO-104;Placebo
30	Rizatriptan for Episodic Dizziness in Vestibular Migraine	Recruiting	NCT02447991	Phase 2, Phase 3	Rizatriptan;Placebo
31	Caroverin and Inner Ear Diseases	Suspended	NCT01174979	Phase 3	Caroverin
32	Autoimmunity in Inner Ear Disease	Terminated	NCT00000361	Phase 3	Corticosteroids;Methotrexate
33	A 6-Month Extension Study of OTO-104 in Meniere's Disease	Terminated	NCT02768662	Phase 3	OTO-104
34	Study of OTO-104 in Subjects With Unilateral Meniere's Disease	Terminated	NCT02717442	Phase 3	OTO-104;Placebo
35	A 6-Month Extension Study of OTO-104 in Meniere's Disease	Terminated	NCT02706730	Phase 3	OTO-104
36	Famvir for Treatment of Hearing in Unilateral Meniere's Disease	Terminated	NCT01526408	Phase 3	Famciclovir;Placebo
37	Latanoprost for the Treatment of Menière's Disease	Unknown status	NCT01973114	Phase 2	Latanoprost
38	Visual Feedback Goggle for Positional Vertigo Treatment	Unknown status	NCT00729885	Phase 1, Phase 2
39	Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy	Unknown status	NCT02247648	Phase 2	tramadol;Placebo
40	The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease	Completed	NCT01950312	Phase 2	gevokizumab
41	A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease	Completed	NCT01267994	Phase 1, Phase 2	Anakinra
42	Study to Evaluate SPI-1005 in Adults With Meniere's Disease	Completed	NCT02603081	Phase 1, Phase 2	SPI-1005
43	A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom	Completed	NCT02265393	Phase 2	OTO-104;Placebo
44	OTO-104 for the Treatment of Meniere's Disease	Completed	NCT01412177	Phase 2	OTO-104;Placebo
45	A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo	Completed	NCT02299804	Phase 2	Levophencynonate Hydrochloric;Placebo
46	Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo	Completed	NCT02046980	Phase 2
47	Effect of V0251 in Acute Vertigo	Completed	NCT01583738	Phase 2	V0251;placebo
48	Prednisone Treatment for Vestibular Neuronitis	Completed	NCT00271791	Phase 2	Prednisone;Prednisone
49	Treatments for Benign Paroxysmal Positional Vertigo (BPPV)	Completed	NCT00000359	Phase 2
50	A Trial of Booklet Based Self Management of Dizziness	Completed	NCT00732797	Phase 2

Search NIH Clinical Center for Labyrinthitis

Cochrane evidence based reviews: labyrinthitis

Sources

Genetic Tests for Labyrinthitis

Sources

Anatomical Context for Labyrinthitis

MalaCards organs/tissues related to Labyrinthitis:

⁴²

Testes, Eye, Brain, Bone, Kidney, Pons, Bone Marrow

Sources

Publications for Labyrinthitis

Articles related to Labyrinthitis:

(show top 50) (show all 219)

#	Title	Authors	Year
1	Pathology in Practice. Opportunistic Pseudomonas aeruginosa infection as cause of otitis media and labyrinthitis in immunocompetent mice. ( 30605387 )	Santagostino SF...Radaelli E	2019
2	A case of external auditory canal osteoma complicated with cholesteatoma, mastoiditis, labyrinthitis and internal auditory canal pachymeningitis. ( 30745589 )	Iaccarino I...Falcioni M	2019
3	Etiology-Specific Mineralization Patterns in Patients with Labyrinthitis Ossificans. ( 30792250 )	Buch K...Sakai O	2019
4	Direction-Changing Positional Nystagmus in Acute Otitis Media Complicated by Serous Labyrinthitis: New Insights into Positional Nystagmus. ( 30870366 )	Choi JW...Kim CH	2019
5	Labyrinthitis Ossificans in a Cynomolgus Macaque (Macaca fascicularis). ( 29650059 )	Balamayooran G....Caudell D.L.	2018
6	Differentiation Between Intralabyrinthine Schwannoma and Contrast-enhancing Labyrinthitis on MRI: Quantitative Analysis of Signal Intensity Characteristics. ( 30020263 )	Bae YJ...Koo JW	2018
7	Gradenigo's Syndrome and Labyrinthitis: Conservative versus Surgical Treatment. ( 30155332 )	Al-Juboori A...Al Hail AN	2018
8	Facial Nerve Stimulation Patterns Associated With Cochlear Implantation in Labyrinthitis Ossificans. ( 30444844 )	Nassiri AM...Rivas A	2018
9	"Emergency" Cochlear Implantation in Labyrinthitis Ossificans Secondary to Polyarteritis Nodosa: How to Face a Rare Entity. ( 30541729 )	Canzi P...Benazzo M	2018
10	Cochlear Implant Associated Labyrinthitis: A Previously Unrecognized Phenomenon With a Distinct Clinical and Electrophysiological Impedance Pattern. ( 29065095 )	Itayem D.A....Carlson M.L.	2017
11	Kawasaki Disease and Labyrinthitis: An Underdiagnosed Complication. ( 28417110 )	Kim K.Y....Seo Y.J.	2017
12	Deterioration of Vestibular Cells in Labyrinthitis. ( 27881797 )	Kaya S....Cureoglu S.	2017
13	Nystagmus in patients with unilateral acute otitis media complicated by serous labyrinthitis. ( 26797398 )	Kim C.H....Shin J.E.	2016
14	Quantitative Assessment of Cochlear Histopathologic Findings in Patients With Suppurative Labyrinthitis. ( 26987015 )	Kaya S....Cureoglu S.	2016
15	Labyrinthitis ossificans after meningitis: Superiority of high-resolution magnetic resonance imaging in demonstration of disease extent compared to high-resolution computed tomography. ( 27114680 )	Vyas S....Khandelwal N.	2016
16	Pathologic Findings of the Cochlea in Labyrinthitis Ossificans Associated with the Round Window Membrane. ( 27221575 )	Kaya S....Cureoglu S.	2016
17	Suppurative labyrinthitis associated with otitis media: 26 years' experience. ( 26718959 )	MaranhALo A.S....Penido N.d.e. .O.	2016
18	Pneumolabyrinth with Labyrinthitis as the Suspected Cause. ( 27115607 )	Nomura K....Himi T.	2016
19	Cochlear changes in serous labyrinthitis associated with silent otitis media: A human temporal bone study. ( 26954857 )	Kaya S....Cureoglu S.	2016
20	Progression of autoimmune inner ear disease to labyrinthitis ossificans: clinical and radiologic correlation. ( 25738715 )	Khoo J.N....Tan T.Y.	2015
21	Rapidly Destructive Autoimmune Labyrinthitis Associated With Ulcerative Colitis. ( 26385058 )	Hwang M....Zuccoli G.	2015
22	The Impact of Postmeningitic Labyrinthitis Ossificans on Speech Performance After Pediatric Cochlear Implantation. ( 26536413 )	Liu C.C....Isaacson B.	2015
23	Labyrinthitis Ossificans: On the Mechanism of Perilabyrinthine Bone Remodeling. ( 25757630 )	Bloch S.L....Friis M.	2015
24	Refractory Positional Vertigo With Apogeotropic Horizontal Nystagmus After Labyrinthitis: Surgical Treatment and Identification of Dysmorphic Ampullae. ( 26208126 )	Ahmed S....Telian S.A.	2015
25	The incidence of tympanogenic labyrinthitis ossificans. ( 25075947 )	Lin H.Y....Lin H.C.	2014
26	Bilateral sensorineural hearing loss and labyrinthitis ossificans secondary to neurosarcoidosis. ( 25189997 )	Dhanjal H....Irving R.M.	2014
27	Clinical outcome after cochlear implantation in patients with unilateral hearing loss due to labyrinthitis ossificans. ( 23921941 )	Hassepass F....Arndt S.	2013
28	High-resolution 3-D T2-weighted imaging in the diagnosis of labyrinthitis ossificans: emphasis on subtle cochlear involvement. ( 23843131 )	Booth T.N....Isaacson B.	2013
29	Labyrinthitis ossificans in a cochlear implant patient with Usher syndrome. ( 23455060 )	Ruiz A.P....Garcia Gomez J.M.	2013
30	Tuberculous otitis media with facial paralysis combined with labyrinthitis. ( 24653900 )	Hwang G.H....Choi J.	2013
31	End-stage labyrinthitis with extensive erosion of the bony labyrinth. ( 22377652 )	Lao Z....Cheng Y.S.	2012
32	Acute labyrinthitis secondary to aural tick infestation. ( 23077807 )	Shibghatullah A.H....Mohamad I.	2012
33	Effect of Ginkgo biloba extract on endotoxin-induced labyrinthitis. ( 21592590 )	Jang C.H....Kang S.I.	2011
34	Auditory and vestibular defects induced by experimental labyrinthitis following herpes simplex virus in mice. ( 21526906 )	Esaki S....Murakami S.	2011
35	Radiology quiz case 2. Labyrinthitis ossificans secondary to suppurative labyrinthitis. ( 21422319 )	Page N....Kearns D.	2011
36	Deafness due to haemorrhagic labyrinthitis and a review of relapses in Streptococcus suis meningitis. ( 20358139 )	Tan J.H....Seet C.S.	2010
37	Labyrinthitis ossificans secondary to autoimmune inner ear disease: a previously unreported condition. ( 20416474 )	Benson A.G.	2010
38	Labyrinthitis ossificans. ( 19300296 )	Xu H.X....Paparella M.M.	2009
39	Labyrinthitis ossificans in a child with sickle cell disease: CT and MRI findings. ( 19415252 )	Liu B.P....Sakai O.	2009
40	Posttraumatic labyrinthitis ossificans with perilymphatic fistulization. ( 19862674 )	AralaA9mak A....Karaali K.	2009
41	Labyrinthitis ossificans: how accurate is MRI in predicting cochlear obstruction? ( 19393413 )	Isaacson B....Roland P.S.	2009
42	Serous labyrinthitis as a manifestation of cat scratch disease: a case report. ( 20519021 )	Kantas I....Papadakis C.E.	2009
43	Meningitis resulting in hearing loss and labyrinthitis ossificans - does the causative organism matter? ( 18246540 )	Douglas S.A....Gibson W.P.	2008
44	Induction of cytomegalovirus-infected labyrinthitis in newborn mice by lipopolysaccharide: a model for hearing loss in congenital CMV infection. ( 18475257 )	Li L....Tsutsui Y.	2008
45	Nitrogen and oxygen molecules in meningitis-associated labyrinthitis and hearing impairment. ( 18084715 )	Klein M....Pfister H.W.	2008
46	Labyrinthitis related to Wegener granulomatosis: magnetic resonance imaging findings. ( 18097336 )	Teszler C.B....Ayache D.	2008
47	Progressive cochleo-vestibular labyrinthitis. ( 17633668 )	Boleas-Aguirre M.S....Perez N.	2007
48	Advancement in post-meningitic lateral semicircular canal labyrinthitis ossificans. ( 17123454 )	Chan C.C....Rajput K.	2007
49	Otogenic cerebellar abscess due to purulent labyrinthitis and defect of the superior semicircular canal and its propagation through the endolymphatic sac. ( 17372752 )	Durisin M....Lenarz T.	2007
50	Pathogenesis of cytomegalovirus-associated labyrinthitis in a guinea pig model. ( 17208485 )	Katano H....Kurata T.	2007

Sources

Genes for Labyrinthitis

Genes related to Labyrinthitis (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CRLF1	Cytokine Receptor Like Factor 1	Protein Coding	16.72	DISEASES inferred ¹⁵
2	IL10RA	Interleukin 10 Receptor Subunit Alpha	Protein Coding	15.42	DISEASES inferred ¹⁵
3	NCS1	Neuronal Calcium Sensor 1	Protein Coding	15.01	DISEASES inferred ¹⁵
4	IGBP1	Immunoglobulin Binding Protein 1	Protein Coding	14.87	DISEASES inferred ¹⁵
5	HINT1	Histidine Triad Nucleotide Binding Protein 1	Protein Coding	14.76	DISEASES inferred ¹⁵
6	HEY2	Hes Related Family BHLH Transcription Factor With YRPW Motif 2	Protein Coding	14.75	DISEASES inferred ¹⁵

Sources

Variations for Labyrinthitis

Sources

Expression for Labyrinthitis

Search GEO for disease gene expression data for Labyrinthitis.

Sources

Pathways for Labyrinthitis

Sources

GO Terms for Labyrinthitis

Sources

Sources for Labyrinthitis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia